• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Alterations in Microbial Diversity are Associated with Treatment Success with RBX2660, a Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection: Results from PUNCH CD 2: a Randomized Double-Blind Placebo-Controlled Trials

Sahil Khanna, MBBS, MS; Gail Hecht, MD; Erik Dubberke,MD, MSPH; Robert Orenstein, DO; Christine Lee, MD; Dale Gerding, MD

Download the presentation (5.9 MB)

Digestive Diseases Week
May 6-9, 2017, Chicago, IL

Summary

  • One dose of RBX2660 administered via enema is more effective than placebo for recurrent CDI
  • Responders to RBX2660
    • Distinct microbiome changes from baseline in contrast to those who fail active treatment
  • Responders to RBX2660
    • Different microbiota composition than responders to placebo
  • Placebo responders demonstrate no changes in microbiota composition after treatment

Conclusions

  • RBX2660 administered via enema is an effective treatment for recurrent CDI
  • Responders to active therapy have distinct microbiome profiles compared to failures
    • Importance of bacterial engraftment
  • Response to active therapy but not to placebo correlates with changes from baseline microbiome
  • Changes in microbial profiles after microbiota-based therapies may predict treatment response

Microbiota Restoration Therapy Presentations Presentations

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us